METHOD FOR ASSESSING THE SEVERITY OF SARS
The present invention relates to a method for assessing the severity of Severe Acute Respiratory Syndrome (SARS) in a patient; said method being based on a severity score consisting of at least: a) a respiratory system score, b) a score determined by the level of pancreatic stone protein/regenerating protein (PSP/reg) in a body fluid sample from said patient. The invention may be used in a healthcare unit for sorting patients to decide the treatment priority
1 . A method for assessing the severity of Severe Acute Respiratory Syndrome (SARS) in a patient, said method being based on a severity score composed of at least:
a) a respiratory system score,
b) a score determined by the level of pancreatic stone protein/regenerating protein (PSP/reg) in a body fluid sample from said patient.
2 . The method of claim 1 for assessing the severity of SARS-CoV-2 (Covid-19).
3 . The method of claim 1 comprising the following steps:
a) Providing a body fluid sample from said patient;
b) Determining the level of pancreatic stone protein/regenerating protein (PSP/reg) in said sample;
c) Determining the PSP/reg score;
d) Determining the respiratory score;
e) Determining the severity score by adding the PSP/reg and respiratory score.
4 . The method of claim 1 wherein the severity score also includes another biomarker score.
5 . The method of claim 4 wherein said biomarker is C-Reactive Protein (CRP).
6 . The method of claim 1 wherein the body fluid sample is a serum, plasma, whole blood sample, saliva, urine, sputum, cerebrospinal fluid, tear fluid, sweat, milk, or extracts from solid tissue or from fecal matter.
7 . The method of claim 1 wherein the respiratory score is obtained by assessing how the patient has difficulties to breath, needs oxygen support or mechanical ventilation (invasive and non-invasive).
8 . The method of claim 1 wherein a severity score of less than 1 is indicating a low risk of clinical complications and/or deteriorations.
9 . The method of claim 1 wherein a severity score greater than 3 is indicative of high risk of developing severe viral sepsis (severe cytokine storm), bacterial sepsis, multiple organ failures and/or death.
10 . The method of claim 1 wherein the level of PSP/reg is determined by ELISA, RIA, EIA, mass spectrometry, microarray analysis or any fluidic assay methods.
11 . Use of the severity score as defined in claim 1 for patient triage, sorting, orientation, positioning and/or stratification in a healthcare unit.